Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 4/2015

01-10-2015 | Gynecologic Oncology

Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer

Authors: Li-ying Zhang, Pei-ling Li, Tian-zhen Wang, Xin-chen Zhang

Published in: Archives of Gynecology and Obstetrics | Issue 4/2015

Login to get access

Abstract

Purpose

DNA methylation is an important epigenetic modification that is frequently altered in cancer. Recent reports showed that the level of 5-hydroxymethylcytosine (5-hmC) was altered in various types of cancers. The influence of DNA methylation in epithelial ovarian cancer (EOC) is not fully understood. Therefore, the aim of the present study was to investigate factors involved in DNA demethylation in EOC compared with normal ovarian tissues.

Methods

We examined the expression of 5-hmC, 5-mC, and TET2 by immunohistochemistry in 130 cases of EOC and 40 cases of normal ovarian tissues. We assessed the prognostic values of 5-hmC, 5-mC, and TET2 in clinical outcome of EOC.

Results

We discovered a significant decrease in 5-hmC and TET2 expression in EOC compared with normal ovarian tissues. In contrast, there was a significant increase in 5-mC expression in EOC compared with normal ovarian tissues. The expression of 5-hmC, 5-mC, and TET2 correlated with pathologic stage, tumor grading, lymph node metastasis, and vascular thrombosis. Furthermore, decreased level of 5-hmC predicts poor prognosis of EOC patients. The expression of 5-hmC was an independent prognostic factor for overall survival of EOC patients.

Conclusions

The data suggest that loss of 5-hmC is an epigenetic event of EOC, and the expression of 5-hmC could serve as a prognostic factor for EOC.
Literature
1.
Arikan SK, Kasap B, Yetimalar H, Yildiz A, Sakarya DK, Tatar S (2014) Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma. Asian Pac J Cancer Prev 15:6087–6094CrossRefPubMed
2.
Rai Bhavana, Bansal Anshuma, Patel Firuza Darius, Sharma Suresh Chander (2014) Radiotherapy for ovarian cancers-redefining the role. Asian Pac J Cancer Prev 15:4759–4763CrossRefPubMed
3.
Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S (2013) Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors. Arch Gynecol Obstet 288(6):1377–1383PubMedCentralCrossRefPubMed
4.
He SY, Shen HW, Xu L, Li XL, Yao SZ (2012) Successful management of mucinous ovarian cancer by conservative surgery in week 6 of pregnancy: case report and literature review. Arch Gynecol Obstet 286(4):989–993PubMedCentralCrossRefPubMed
5.
Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18:19–32CrossRef
6.
Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U (2014) The emerging role of anti-angiogenic therapy in ovarian cancer (Review). Int J ncol 44:1417–1424
7.
YiChen Wu, Ling ZhiQiang (2014) The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histol Histopathol 29:991–997
8.
9.
Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19:698–711CrossRefPubMed
10.
11.
12.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935PubMedCentralCrossRefPubMed
13.
14.
Münzel M, Globisch D, Carell T (2011) 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 50:6460–6468CrossRefPubMed
15.
Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden W, Schüller U, Carell T, Kretzschmar HA (2012) Low values of 5-hydroxymethylcytosine (5hmC), the ‘sixth base’, are associated with anaplasia in human brain tumors. Int J Cancer 131:1577–1590CrossRefPubMed
16.
17.
Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2:627–637PubMedCentralPubMed
18.
19.
Iyer LM, Thiliani M, Rao A, Aravind L (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8:1698–1710PubMedCentralCrossRefPubMed
20.
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y (2013) Tumor development is associated with decrease of TET gene expression and 5-methlcytosine hydroxylation. Oncogene 32:663–669PubMedCentralCrossRefPubMed
21.
Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, Min J, Nicholson T, Chen T, Xu G, Shi Y, Zhang K, Shi YG (2011) Genome-wide regulation of 5 hmC, 5 mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42:451–464PubMedCentralCrossRefPubMed
22.
Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135–1146PubMedCentralCrossRefPubMed
23.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30PubMedCentralCrossRefPubMed
24.
Gambichler T, Sand M, Skrygan M (2013) Loss of 5- hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 23:218–220CrossRefPubMed
25.
Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M, Sato Y (2013) In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci 104:1705–1710CrossRefPubMed
Metadata
Title
Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer
Authors
Li-ying Zhang
Pei-ling Li
Tian-zhen Wang
Xin-chen Zhang
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 4/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3704-3

Other articles of this Issue 4/2015

Archives of Gynecology and Obstetrics 4/2015 Go to the issue

General Gynecology

Association of the intercellular adhesion molecule-1 (ICAM-1) gene polymorphisms with endometriosis: a systematic review and meta-analysis

Maternal-Fetal Medicine

The significance of a uterine rupture in subsequent births

Reply

Response to: Relationship between preeclampsia, gestational hypertension, and vitamin D receptor (VDR) gene polymorphisms

Reply

Surgery, endometriosis-related infertility and negative impact on ovarian reserve: “which came first, the hen or the egg?” An unresolved dilemma

Gynecologic Oncology

Dysregulated microRNAs involved in the progression of cervical neoplasm

General Gynecology

Perioperative outcomes and prospective patient reported outcome measures for transvaginal mesh surgery